Literature DB >> 7666562

Transcriptional silencing of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by the Krüppel-associated box repressor domain targeted to the transactivating response element.

G Pengue1, A Caputo, C Rossi, G Barbanti-Brodano, L Lania.   

Abstract

The evolutionarily conserved protein domain, called the Krüppel-associated box (KRAB), present in the amino termini of a large number of Krüppel-type zinc finger proteins is a strong repressor domain. In order to develop novel strategies to control human immunodeficiency virus type 1 (HIV-1) gene expression, we constructed a series of expression vectors expressing the wild-type Tat or Tat transdominant negative mutants fused to the KRAB repressor domain. We found that the KRAB domain tethered to the transactivating response element is able to suppress both basal and Tat-mediated activity of HIV-1 long terminal repeat-driven gene expression. These results suggest that the KRAB repressor domain fused to the Tat transdominant negative mutants can be successfully employed to control HIV-1 gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666562      PMCID: PMC189563     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.

Authors:  L S Tiley; S J Madore; M H Malim; B R Cullen
Journal:  Genes Dev       Date:  1992-11       Impact factor: 11.361

Review 2.  Antisense RNA.

Authors:  Y Eguchi; T Itoh; J Tomizawa
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

3.  Gene therapy. Intracellular immunization.

Authors:  D Baltimore
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

4.  Krüppel-associated boxes are potent transcriptional repression domains.

Authors:  J F Margolin; J R Friedman; W K Meyer; H Vissing; H J Thiesen; F J Rauscher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

5.  Enhanced activity of human G6PD promoter transfected in HeLa cells producing high levels of HIV-1 Tat.

Authors:  M V Ursini; T Lettieri; M Braddock; G Martini
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

6.  Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant.

Authors:  P G Balboni; R Bozzini; S Zucchini; P C Marconi; M P Grossi; A Caputo; R Manservigi; G Barbanti-Brodano
Journal:  J Med Virol       Date:  1993-12       Impact factor: 2.327

7.  Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.

Authors:  N Modesti; J Garcia; C Debouck; M Peterlin; R Gaynor
Journal:  New Biol       Date:  1991-08

8.  Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells.

Authors:  Y Luo; S J Madore; T G Parslow; B R Cullen; B M Peterlin
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.

Authors:  C D Southgate; M R Green
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

Review 10.  Progress towards gene therapy for HIV infection.

Authors:  M Yu; E Poeschla; F Wong-Staal
Journal:  Gene Ther       Date:  1994-01       Impact factor: 5.250

View more
  10 in total

1.  OTK18, a zinc-finger protein, regulates human immunodeficiency virus type 1 long terminal repeat through two distinct regulatory regions.

Authors:  Masahide Horiba; Lindsey B Martinez; James L Buescher; Shinji Sato; Jenae Limoges; Yunquan Jiang; Clinton Jones; Tsuneya Ikezu
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

2.  Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat.

Authors:  Manabu Taura; Eric Song; Ya-Chi Ho; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-22       Impact factor: 11.205

3.  In vivo transcriptional regulation of the human immunodeficiency virus in the central nervous system in transgenic mice.

Authors:  J Kurth; J M Buzy; L Lindstrom; J E Clements
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Krüppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements.

Authors:  G Pengue; L Lania
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

5.  A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins.

Authors:  S S Kim; Y M Chen; E O'Leary; R Witzgall; M Vidal; J V Bonventre
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  From repression domains to designer zinc finger proteins: a novel strategy of intracellular immunization against HIV.

Authors:  H J Thiesen
Journal:  Gene Expr       Date:  1996

Review 7.  Chromatin organization and virus gene expression.

Authors:  Paul M Lieberman
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 8.  Targeting HIV-1 proviral transcription.

Authors:  Alex Olson; Binita Basukala; Wilson W Wong; Andrew J Henderson
Journal:  Curr Opin Virol       Date:  2019-08-29       Impact factor: 7.121

9.  Transcriptional regulators TRIM28, SETDB1, and TP53 are aberrantly expressed in porcine embryos produced by in vitro fertilization in comparison to in vivo- and somatic-cell nuclear transfer-derived embryos.

Authors:  Jennifer Hamm; Kim Tessanne; Clifton N Murphy; Randall S Prather
Journal:  Mol Reprod Dev       Date:  2014-04-16       Impact factor: 2.609

10.  Transformation induced by Ewing's sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1.

Authors:  D Chan; T J Wilson; D Xu; H E Cowdery; E Sanij; P J Hertzog; I Kola
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.